You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 690 High safety and efficacy of CRISPR-Based non-viral PD1 locus specific Integrated Anti-CD19 CAR-T cells (BRL-201) in treating relapsed or refractory non-Hodgkin’s lymphoma: first-in-human phase I study

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
690 High safety and efficacy of CRISPR-Based non-viral PD1 locus specific Integrated Anti-CD19 CAR-T cells (BRL-201) in treating relapsed or refractory non-Hodgkin’s lymphoma: first-in-human phase I study

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023294018
Dec 20236606
Jan 20248306
Feb 20245002
Mar 20244405
Apr 20243802
May 20244605
Jun 20243304
Jul 202411403
Aug 20243606
Sep 20242907
Oct 20245206
Nov 20242101
Dec 20242005
Jan 20252209
Feb 2025202
Mar 2025003
Apr 2025002
May 2025007
Jun 2025204
Total9520103